49640-66-6

Usage

Uses

Used in Chemical Synthesis:
1-(hydroxymethyl)cyclopropanecarboxylic acid(SALTDATA: FREE) is used as a building block for the synthesis of other organic compounds, leveraging its unique cyclopropane ring and hydroxymethyl group to create a diverse array of chemical products.
Used in Pharmaceutical Industry:
1-(hydroxymethyl)cyclopropanecarboxylic acid(SALTDATA: FREE) is utilized as a versatile intermediate in the production of pharmaceuticals. Its distinctive structure allows it to be incorporated into the development of new drugs, potentially contributing to advancements in medicinal chemistry.
Used in Agrochemical Production:
In the agrochemical sector, 1-(hydroxymethyl)cyclopropanecarboxylic acid(SALTDATA: FREE) serves as an important intermediate. Its application aids in the formulation of agrochemicals, which are essential for enhancing crop protection and yield.
Overall, 1-(hydroxymethyl)cyclopropanecarboxylic acid(SALTDATA: FREE) holds a broad spectrum of potential applications across various industries, particularly in chemistry and pharmaceuticals, where its unique structural attributes facilitate innovative synthesis and development processes.

Upstream product

• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 
• 51175-79-2 methyl α-bromocyclobutanecarboxylate 
• 67567-55-9 1-(methoxymethyl)cyclopropanecarboxylic acid 
• 113020-21-6 1,1-cyclopropanedicarboxylic acid monomethyl ester 
• 6914-71-2 dimethyl 1,1-cyclopropanedicarboxylate 
• 35120-18-4 ethyl 1-bromocyclobutane-1-carboxylate 
• 2983-89-3 ethyl α-bromocyclobutanecarboxylate 

Downstream Products

• 1445981-42-9 1-cyclopropyl-4-[[1-(2,5-dichlorophenoxymethyl)cyclopropyl]carbonyl]-1,2,3,4-tetrahydroquinoxaline trifluoroacetate 
• 1445984-97-3 tert-butyl 3-[2,5-dichloro-4-([1-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]cyclopropyl]methoxy)phenyl]propanoate 
• 1445981-44-1 3-[2,5-dichloro-4-([1-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]cyclopropyl]methoxy)phenyl]propanoic acid trifluoroacetate 
• 1445981-46-3 3-[2,5-dichloro-4-([1-[(4-cyclopropyl-1,2,3,4-tetrahydroquinoxalin-1-yl)carbonyl]cyclopropyl]methoxy)phenyl]-N-methyl-N-[(2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl]propanamide trifluoroacetate 
• 1445983-59-4 (4-cyclopropyl-3,4-dihydroquinoxalin-1(2H)-yl)(1-((2,5-dichlorophenylthio)methyl)cyclopropyl)methanone 

Relevant academic research and scientific papers

BTK INHIBITORS

Provided are compounds of Formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R7, R8, R9, A1, A2, Q1, Q2, Q3, A, Z, m and n are as defined herein; pharmaceutical compositions comprising said compounds or pharmaceutically acceptable salts thereof, and pharmaceutically acceptable excipients; and methods of treating a disorder responsive to inhibition of Bruton's tyrosine kinase using said compounds, or pharmaceutically acceptable salts thereof, or said pharmaceutical compositions.

Nitroxide derivative of ROCK kinase inhibitor

The invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound shown represented by structural formula I shown in the description, or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a deuterated isotope derivative, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof; and in the formula I, ring A is a substituted or unsubstituted heteroaromatic ring, X is selected from (CH2)n, n is selected from 0, 1, 2 and 3, R is a substituent group of terminal -O-NO2, R is selected from hydrogen, a hydroxyl group, halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group and a substituted or unsubstituted heteroalkyl group, and R and R are respectively and independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted naphthenic base or an amino protecting group, or R and R are connected to form a substituted or unsubstituted cyclic heteroalkyl group. The compound has a high-activity inhibition effect on ROCK kinase.

POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS

The present invention relates to compounds of Formula (I) and pharmaceutically acceptable compositions thereof, useful as toll-like receptor 7/8 (TLR7/8) antagonists. In Formula (I), Ring A is aryl or heteroaryl; Ring B is aryl or heteroary; and X is C(R4)2, O, NR4, S, S(R4), or S(R4)2.

Cu-Catalyzed Alkynylation of Unactivated C(sp3)-X Bonds with Terminal Alkynes through Directing Strategy

In this letter, we report an efficient and concise protocol for Cu-catalyzed cross-coupling of unactivated alkyl halides/peusudohalides with terminal alkynes to afford internal alkynes with the assistance of various amides as directing groups. Different alkyl halides/pseudohalides exhibited excellent reactivities, and the inactivated alkyl chlorides and sulfonates showed better reactivity than bromides/iodides. This is the first successful example to apply alkyl chlorides and sulfonates directly in cross-coupling with terminal alkynes in the absence of any additives. A Cu catalyst was found to be more effective than other transition metal catalysts. This reaction also exhibited a broad substrate scope with respect to terminal alkynes.

AROMATIC HETEROCYCLIC COMPOUND

The compound represented by the general formula: wherein ring A is benzene which may be substituted and the like; ring B is benzene which may be substituted and the like; X is a single bond and the like; Y is alkyl which may be substituted and the like; Z is CR1 or nitrogen atom; R1 is hydrogen and the like; R2 is alkyl which may be substituted and the like or a pharmaceutically acceptable salt thereof is useful as a prevention/treatment agent of obesity, diabetes, and the like.

NON-SYSTEMIC TGR5 AGONISTS

Compounds of structure (I), or a stereoisomer, tautomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, R3, R4, R8, R9, R10, R11, R12, A1, A2, X, Y and Z are as defined herein. Uses of such compounds as TGR5 antagonists and for treatment of various indications, including Type II diabetes meletus are also provided.

ARYL-AMINO SUBSTITUTED PYRROLOPYRIMIDINE MULTI-KINASE INHIBITING COMPOUNDS

Compounds represented by Formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, are inhibitors of least two of the Abl, Aurora-A, Blk, c-Raf, cSRC, Src, PRK2, FGFR3, Flt3, Lck, Mekl, PDK-1, GSK3?, EGFR, p70S6K, BMX, SGK, CaMKII, Tie-2

Regioselective synthesis of α,α-dialkylcyclopentanones from 1-hydroxycyclobutanecarboxylic acid or from O-protected cyclobutanone cyanohydrin

1-(1-Hydroxyalkyl)cyclobutanols 4a-f, readily available either from 1-hydroxycyclobutane carboxylic acid or from O-protected cyclobutanone cyanohydrin, appeared the most suitable precursors for a regioselective synthesis of cyclopentanones α,α- disubstituted with various similar or different alkyl, alkenyl, aryl or cycloalkyl groups. The key steps consist of acid or Grignard reagent induced C4→C5 ring expansions.

A new cyclobutane ring contraction: The base-induced rearrangement of an a-bromocyclobutanecarboxylic ester

Contrary to previous reports, reactions of methyl α-bromocyclobutanecaiboxylate 6b with potassium hydroxide or carbonate lead exclusively to 1-(hydroxymethyl)cyclopropanecarboxylic acid 7.